<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369945">
  <stage>Registered</stage>
  <submitdate>25/05/2016</submitdate>
  <approvaldate>17/06/2016</approvaldate>
  <actrnumber>ACTRN12616000796482</actrnumber>
  <trial_identification>
    <studytitle>Isothermic hydration : Effects on maternal body temperature and fetal outcomes</studytitle>
    <scientifictitle>The effect of isothermic hydration on maternal body temperature and fetal outcomes for parturients undergoing cesarean section under spinal anesthesia</scientifictitle>
    <utrn>U1111-1183-1466</utrn>
    <trialacronym>IHMBTFO</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>spinal anesthesia for cesarean section</healthcondition>
    <healthcondition>hypothermia</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Other anaesthesiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>parturients undergoing cesarean section under spinal anesthesia will be randomly divided into two groups. control group will be hydrated with intravenous infusion of Lactated Ringer's solution 10ml/kg at room temperature and the study group will be hydrated with  10ml/kg intravenous Lactated Ringer's solution at 37 degrees celcius before the administration of spinal anesthesia. intravenous infusion continued with a rate of 4ml/min in each group till the end of surgery at 37 degrees celcius in study group and at 21 degrees celcius in the control group. the temperature of the study infusion solution was kept constant by the warming device. </interventions>
    <comparator>Intravenous infusion of the compator group will be at room temperature (21 degrees celcius).</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Maternal body temperature, assessed with a digital thermometer at tympanic membrane.</outcome>
      <timepoint>basal body temperature of the parturient will be recorded on enterance to operation room. the body temperature of the parturient will than be recorded every minute till 10 minutes after spinal anesthesia. and every 5 minutes till 30 minutes or at the end of the operation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>fetal cord blood gas pH value, assessed by cord blood gas analysis.</outcome>
      <timepoint>cord blood gas analysis of the newborn will be assessed immediately after delivery </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>APGAR scores</outcome>
      <timepoint>1 minute and 5 minutes following birth</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>parturients consenting to spinal anesthesia for cesarean section</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients rejecting spinal anesthesia or any contraindication for spinal anesthesia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>computer generated sequence is used for sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods>following a pilot study, G*power statistical analysis program will be used to determine sample size for a 0,90 power with a statistical significance of 0,05.Kolmogorov-Smirnow and Shapiro Wilk tests, repeated measures ANOVA, friedman test, Tukey HSD, chi-square test, Spearman Rho correlation test will be used for statistical analysis.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2016</anticipatedstartdate>
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate>31/12/2016</anticipatedenddate>
    <actualenddate>30/12/2016</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>kirsehir</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mehmet Canturk</primarysponsorname>
    <primarysponsoraddress>Medical doctor at government hospital
asikpasa mahallesi
sehit ahmet dogangun caddesi
caglar apartmani
30/8
merkez/kirsehir/Turkey p.k.40100</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>mehmet canturk</fundingname>
      <fundingaddress>Kirsehir ahi evran universitesi egitim ve arastirma hastanesi
asikpasa mahallesi
sehit ahmet dogangun caddesi
caglar apartmani
30/8
merkez/kirsehir/Turkey p.k.40100</fundingaddress>
      <fundingcountry>Turkey</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>preserving normothermia decreases morbidity and mortality in patients undergoing surgery. Intravenous infusion is usually provided by solutions present at operation theatre  at room temperature and this condition provokes a decrease in body temperature and results in shivering. the decrease in maternal body temperature and resulting shivering and vasoconstriction may affect the fetal outcomes. in this study we are investigating if isothermic hydration will help to preserve maternal normothermia and improves fetal outcomes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Turgut Ozal University Clinical Trials Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/05/2016</ethicapprovaldate>
      <hrec>99950669/116</hrec>
      <ethicsubmitdate>29/04/2016</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mehmet Canturk</name>
      <address>Kirsehir Ahi Evran Universitesi Egitim ve Arastirma Hastanesi 3. Kat Ameliyathane Kervansaray Mahallesi 2019. sokak no:1 p.k.40100 kirsehir</address>
      <phone>+905053574372</phone>
      <fax />
      <email>drmcanturk@gmail.com</email>
      <country>Turkey</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mehmet Canturk</name>
      <address>Kirsehir Ahi Evran Universitesi Egitim ve Arastirma Hastanesi 3. Kat Ameliyathane Kervansaray Mahallesi 2019. sokak no:1 p.k.40100 kirsehir</address>
      <phone>+905053574372</phone>
      <fax />
      <email>drmcanturk@gmail.com</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mehmet Canturk</name>
      <address>Kirsehir Ahi Evran Universitesi Egitim ve Arastirma Hastanesi 3. Kat Ameliyathane Kervansaray Mahallesi 2019. sokak no:1 p.k. 40100 kirsehir</address>
      <phone>+905053574372</phone>
      <fax />
      <email>drmcanturk@gmail.com</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mehmet Canturk</name>
      <address>Kirsehir Ahi Evran Universitesi Egitim ve Arastirma Hastanesi 3. Kat Ameliyathane Kervansaray Mahallesi 2019. sokak no:1 p.k.+9040100 kirsehir</address>
      <phone>+905053574372</phone>
      <fax />
      <email>drmcanturk@gmail.com</email>
      <country>Turkey</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>